Eli Lilly & Co. agreed to buy gene-editing biotech company Verve Therapeutics Inc. for $1.3 billion, the obesity drugmaker’s ...

Eli Lilly has confirmed plans for a $1.3 billion takeover bid for Verve Therapeutics, upgrading a collaboration between the ...

Eli Lilly's stock price has over-corrected following a downgrade in its outlook following the adjustment for acquisition ...

Eli Lilly will acquire gene-editing startup Verve Therapeutics for up to $1.3 billion, the companies said on Tuesday, sending ...

Eli Lilly and Co. is shelling out $1 billion to buy a Boston biotech known for genetic medicines for cardiovascular disease.